This paper is only available as a PDF. To read, Please Download here.
Background. The current study compared the immunocytochemical expression of estrogen (ER) and progesterone (PgR) receptors by malignant breast cells to the hormone receptor concentrations reported from radioligand assays. These values were examined in relation to DNA ploidy and the fraction of cells in S phase.
Methods. ER and PgR concentrations, DNA ploidy, and S-phase fractions were measured by standard techniques with 124 samples of invasive ductal carcinoma. Suspensions of tumor cells were examined by immunocytochemical assay (ICA) for the percentages of ER and PgR positive cells.
Results. Twenty-six of the 38 tumors from patients 50 years of age or younger were classified as high S-phase fraction, and 28 tumors had aneuploid levels of DNA. The 20 ER positive tumors each contained less than 100 fmol/mg. Thirty-nine of the 86 tumors from patients older than 50 years were classified as high S phase, and 41 were aneuploid. Sixty-five samples were considered ER positive by radioligand assay. ICA showed that tumors in either age group with less than 40 fmol/mg did not contain ER positive cells. The proportion of samples with PgR levels between 10 and 100 fmol/mg was small, and fewer PgR positive tumors were categorized as negative when examined by ICA for receptor containing cells. The reclassification of the hormone receptor status of a tumor based on ICA appeared to be independent of S-phase and ploidy values.
Conclusions. Tumors that are classified as ER or PgR positive based on accepted cutoff values for radioligand assays may actually be receptor negative because the tumors do not appear to contain receptor positive cells.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Surgery
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- The interaction of estrogen receptor status and race in predicting prognosis for stage I breast cancer patients.Surgery. 1986; 100: 599-605
- Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis and histopathologic grading.Cancer. 1984; 54: 2237-2242
- The predictive value of estrogen and progesterone receptors concentrations on the clinical behavior of breast cancer in women.Cancer. 1986; 57: 1171-1180
- Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer.Cancer Res. 1987; 47: 4729-4735
- Aneuploid DNA content and high S-phase fraction of tumor cells are related to poor prognosis in patients with primary breast cancer.Eur J Cancer Clin Oncol. 1987; 23: 277-282
- Impact of flow cytometry on predicting recurrence and survival in breast cancer patients.Breast Cancer Res Treat. 1985; 5: 117-128
- Concentration of cell-cycle kinetics, hormone receptors, histopathology, and model status in human breast cancer.Cancer. 1984; 54: 1586-1590
- DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens.Cancer. 1988; 61: 420-427
- Cell kinetics as a prognostic marker in node negative breast cancer.Cancer. 1985; 36: 1982-1987
- Practical breast carcinoma cell kinetics: review and update.Breast Cancer Res Treat. 1984; 4: 79-88
- Tumor—proliferative activity, progesterone receptor status, estrogen receptor level and clinical outcome of estrogen receptor-positive advanced breast cancer.Cancer Res. 1990; 50: 2958-2962
- Flow cytometry of breast carcinoma, I: relation of DNA ploidy level to histology and estrogen receptor.Cancer. 1981; 48: 985-988
- Tumor DNA ploidy as an independent prognostic factor in breast cancer.Br J Cancer. 1987; 56: 637-642
- The influence of age on the DNA ploidy levels of breast tumors.Eur J Cancer Clin Oncol. 1983; 19: 623-628
- Prognostic significance of the DNA content of human breast cancer.Br J Surg. 1989; 74: 133-136
- Prognostic value of DNA ploidy and S-phase fraction in relation to estrogen receptor content and clinicopathological variables in primary breast cancer.Eur J Cancer Clin Oncol. 1989; 25: 301-309
- Endocrine therapy of metastatic breast cancer.J Endocrinol Invest. 1989; 12: 357-372
- The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer.J Clin Oncol. 1989; 7: 1474-1484
- Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen chemotherapy in primary breast cancer.J Clin Oncol. 1983; 1: 227-241
- ER and responses to chemotherapy and hormonal therapy in advanced breast cancer.N Engl J Med. 1978; 299: 1330-1334
- The value of estrogen and progesterone receptors in the treatment of breast cancer.Cancer. 1980; 46: 2884-2888
- Steroid hormone receptors in breast cancer.Cancer. 1984; 53: 630-643
- Immunocytochemical analysis of estrogen receptors in human breast carcinomas.Arch Surg. 1990; 125: 107-113
- Comparison of immunocytochemical and steroid binding assays for estrogen receptor in human breast cancers.Cancer Res. 1985; 45: 293-304
- Estrogen receptor analysis: correlation of biochemical and immunochemical methods using antireceptor antibodies.Arch Pathol Lab Med. 1985; 109: 716-722
- Immunohistologic localization of estrogen receptors in breast cancer with monoclonal antibodies: correlations with biochemistry and clinical endocrine response.Cancer. 1985; 55: 1513-1518
- Clinical usefulness of estrogen receptor immunocytochemistry in human breast cancer.Tumori. 1992; 78: 287-290
- Estrogen and progesterone receptor detection in archival formalin-fixed, paraffin-embedded tissue from breast carcinoma: a comparison of immunohistochemistry with the detran-coated charcoal assay.Mod Pathol. 1992; 5: 79-84
- Immunocytochemical analysis of hormone receptors with malignant cells separated from human mammary tumors.Am J Clin Pathol. 1994; 102: 68-71
- Manual for staging of cancer.in: 3rd ed. Lippincott, Philadelphia1988: 145-148
- Measurement of estrogen and progesterone receptors in human breast tumors: enzyme immuno assay versus binding assay.J Clin Oncol. 1990; 8: 1025-1035
- Growth fractions and estrogen receptors in human breast cancer as determined in situ with monoclonal antibodies.Am J Pathol. 1987; 129: 486-492
- Proliferative activity and steroid receptors determined by immunohistochemistry in adjacent frozen sections of 102 breast carcinomas.Arch Pathol Lab Med. 1989; 113: 854-857
- The correlations of K; 67 growth factor and ERICA in breast cancer.Mod Pathol. 1992; 5: 220-223
- Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer: correlation of histopathology and prognostic factors.Ann Surg. 1993; 218: 13-21
- The relationship between growth factors and estrogen receptors in human breast carcinoma as determined by immunohistochemical staining.J Pathol. 1989; 158: 203-211
- Immunohistochemical demonstration of cell proliferation and estrogen receptor status in human breast cancer.Acta Pathol Japonica. 1990; 40: 902-907
Accepted: June 27, 1994
*Supported in part by The Baptist Hospitals Foundation.
© 1995 Mosby-Year Book, Inc. Published by Elsevier Inc.